Swiss pharmaceutical company Novartis AG has announced plans to sell its Indian arm to a consortium led by ChrysCapital. This transaction will see three acquirers—WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners—collectively purchasing the promoter stake in the company.

Details of the Transaction

The agreement marks a significant shift for Novartis in the Indian market, as it aims to streamline its operations and focus on core areas. The consortium's acquisition is expected to provide a new direction for the Indian subsidiary, potentially enhancing its growth prospects in the region.

According to a report by NDTV Business (Profit), the completion of this sale will allow Novartis to concentrate on its strategic priorities while enabling the new owners to leverage their expertise in the pharmaceutical sector. The deal underscores the ongoing trend of consolidation within the industry, as companies seek to optimize their portfolios and adapt to changing market dynamics.

As the transaction progresses, further details regarding the financial aspects and future plans for the subsidiary are anticipated. This move by Novartis reflects its commitment to maintaining a competitive edge in the global pharmaceutical landscape.